How do you choose antibiotic treatment?

BMJ

Volumn 318, Issue 7198, 1999, Pages 1614-

  Leibovici, Leonard ^a   Shraga, Ilana ^a   Andreassen, Steen ^b   Pauker, Stephen G ^c   Rothberg, Michael ^c   Weinberg, Julius R ^d   Duerden, Brian I ^d   Drickamer, Margaret A ^e  

^a TEL AVIV UNIVERSITY   (Israel)

^b AALBORG UNIVERSITY   (Denmark)

^c TUFTS MEDICAL CENTER   (United States)

^d PUBLIC HEALTH ENGLAND   (United Kingdom)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; CEFOTAXIME; CEFUROXIME; CEPHALOSPORIN DERIVATIVE; GENTAMICIN; IMIPENEM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; COST BENEFIT ANALYSIS; DRUG CHOICE; DRUG COST; HUMAN; INFECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

ANTI-BACTERIAL AGENTS; COST-BENEFIT ANALYSIS; DECISION MAKING; HUMANS; INTERPROFESSIONAL RELATIONS;

EID: 0033549314     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.318.7198.1614     Document Type: Article

References (40)

1. Dolan JG, Bordley Dr., Polito R. Initial management of serious urinary tract infection: epidemiological guidelines. J Gen Intern Med 1989; 4: 190–194.
2. Esposito AL, Gleckman RA, Cram S, Crowley M, McCabe F, Drapkin MS. Community-acquired bacteremia in the elderly: analysis of one hundred consecutive episodes. J Am Geriatr Soc 1980; 28: 315–319.
3. Jones GR, Lowes JA. The systemic inflammatory response syndrome as predictor of bacteraemia and outcome from sepsis. Q J Med 1996; 89: 515–522.
4. Meyers BR, Sherman E, Mendelson MH, Velasquez G, Srulevitch-Chin E, Hubbard M, Hirschman SZ. Bloodstream infections in the elderly. Am J Med 1989; 86: 379–384.
5. Gransden WR, Eykyn SJ, Phillips I, Rowe B. Bacteremia due to Escherichia coli: a study of 861 episodes. Rev Infect Dis 1990; 12: 1008–1018.
6. Moore RD, Smith CR, Lipsky JJ, Mellits ED, Lietman PS. Risk factors for nephrotoxicity in patients treated with aminoglycosides. Ann Intern Med 1984; 100: 352–357.
7. Berman JR, Zaran FK, Rybak MJ. Pharmacy-based antimicrobial-monitoring service. Am J Hosp Pharm 1992; 49: 1701–1706.
8. Standing Medical Advisory Committee, Sub-Group on Antimicrobial Resistance. The path of least resistance. London: Department of Health, 1998 (www.doh.gov.uk/smac1.htm; accessed 11 May 1999.)
9. Tomasz A. Multiple antibiotic resistant pathogenic bacteria. N Engl J Med 1994; 330: 1247–1251.
10. Morris JG, Shay DK, Hebden JN, McCarter RJ, Perdue BE, Jarvis W, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995; 123: 250–259.
11. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, et al. Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994; 344: 1329–1332.
12. Burwen Dr., Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial Gram-negative bacilli in the United States. National nosocomial infections surveillance system. J Infect Dis 1994; 170: 1622–1625.
13. Ballow CH, Schentag JJ. Trends in antibiotic utilization and bacterial resistance. Report of the National Nosocomial Resistance Surveillance Group. Diagn Microbiol Infect Dis 1992; 15(suppl 2): S37-S42.
14. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Johnson MP, Ramphal R, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115: 585–590.
15. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989; 23: 441–451.
16. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35: 1284–1290.
17. Leibovici L, Samra Z, Konigsberger H, Drucker M, Ashkenazi S, Pitlik SD. Long-term survival following bacteremia or fungemia. JAMA 1995; 274: 807–812.
18. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244: 379–386.
19. Holloway JJ, Craig CR, Moore RD, Feroli ER, Lietman PS. Comparative cost-effectiveness of gentamycin and tobramicin. Ann Intern Med 1984; 101: 764–769.
20. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, Shusterman NH, Strom BL. What is the cost of nephrotoxicity associated with aminoglycosides? Ann Intern Med 1987; 107: 900–909.
21. Garrelts JC, Horst WD, Silkey B, Gagnon S. A pharmacoeconomic model to evaluate antibiotic costs. Pharmacotherapy 1994; 14: 438–445.
22. Leibovici L, Shraga I. Side-effects of antibiotic drugs: Meta-analysis of observational data. J Hosp Infect 1998; 40(suppl A): W4C.
23. Perl TM, Dvorak M, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA 1995; 274: 338–345.
24. Quartin AA, Schein RMH, Kett DH, Peduzzi PN. Magnitude and duration of the effect of sepsis on survival. JAMA 1997; 277: 1058–1063.
25. Mark DB. Economic analysis methods and endpoints. In: CaliffRM,MarkDB,WagnerGS, eds. Acute coronary care in the thrombolytic area. St Louis: Mosby Year Book, 1995: 167–182.
26. M⊘ller JK. Antimicrobial usage and microbial resistance in a university hospital during a seven-years period. J Antimicrob Chemother 1989; 24: 983–992.
27. Sundman K, Arneborn P, Blad L, Sjoberg L, Vikerfors T. One bolus dose of gentamycin and early oral therapy versus cefotaxime and subsequent oral therapy in the treatment of febrile urinary tract infection. Eur J Clin Microbiol Infect Dis 1997; 16: 455–458.
28. Burke JP. Antibiotic resistance squeezing the balloon? JAMA 1998; 280: 1270–1271.
29. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial klebsiella. JAMA 1998; 280: 1233–1237.
30. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124: 884–890.
31. Evans RS, Classen DC, Pestotnik SL, Lundsgaarde HP, Burke JP. Improving empiric antibiotic selection using computer decision support. Arch Intern Med 1994; 154: 878–884.
32. Leibovici L, Gitelman V, Yehezkelli Y, Poznanski O, Milo G, Paul M, Ein-Dor P. Improving empirical antibiotic treatment: Prospective, nonintervention testing of a decision support system. J Intern Med 1997; 242: 395–400.
33. Goldratt E. The goal. Great Barrington, MA: North River Press, 1992.
34. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistence during therapy. Ann Intern Med 1991; 115: 585–590.
35. Levy SB. The antibiotic paradox: how miracle bugs are destroying the miracle. New York: Plenum, 1992.
36. Alliance for the Prudent Use of Antibiotics (www.healthsci.tufts.edu/apua/apua.html; accessed 11 May 1999.)
37. Weiner J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA. Multiple antibiotic resistent klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281: 517–523.
38. American College of Physicians. Ethics manual. Ann Intern Med 1998; 128: 576–594.
39. Sulmasy DP. Physicians, cost control, and ethics. Ann Intern Med 1992; 116: 920–926.
40. Hall MA, Berenson RA. Ethical practice in managed care: a dose of realism. Ann Intern Med 1998; 128: 395–402.